Stock analysts at StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) in a research note issued to investors on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Stock Performance
Aeterna Zentaris stock opened at $3.70 on Monday. The firm has a market cap of $6.63 million, a PE ratio of -0.25 and a beta of 1.55. Aeterna Zentaris has a 12 month low of $3.96 and a 12 month high of $12.00. The stock’s 50 day simple moving average is $4.70 and its two-hundred day simple moving average is $6.30.
About Aeterna Zentaris
See Also
- Five stocks we like better than Aeterna Zentaris
- Differences Between Momentum Investing and Long Term Investing
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- Dividend Capture Strategy: What You Need to Know
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- What does consumer price index measure?
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.